Published in Head Neck on November 20, 2012
The symptom burden of treatment-naive patients with head and neck cancer. Cancer (2014) 0.84
Nomogram for predicting symptom severity during radiation therapy for head and neck cancer. Otolaryngol Head Neck Surg (2014) 0.80
Intensive nutritional counseling improves PG-SGA scores and nutritional symptoms during and after radiotherapy in Korean cancer patients. Support Care Cancer (2014) 0.80
Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiother Oncol (2016) 0.77
Attitudes of oncologists towards palliative care and the Edmonton Symptom Assessment System (ESAS) at an Ontario cancer center in Canada. Support Care Cancer (2014) 0.76
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys (2016) 0.75
Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module. Balkan Med J (2016) 0.75
Confounding factors associated with oral mucositis assessment in patients receiving chemoradiotherapy for head and neck cancer. Support Care Cancer (2017) 0.75
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32
Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol (2008) 7.97
The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer (1999) 7.87
Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer (2000) 7.25
When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain (1995) 5.97
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain (2003) 4.24
It's not over when it's over: long-term symptoms in cancer survivors--a systematic review. Int J Psychiatry Med (2010) 3.01
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol (2006) 2.84
Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr (2007) 2.63
Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol (2006) 2.45
Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys (2007) 2.40
Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer (2011) 2.18
NCCN clinical practice guidelines in oncology: palliative care. J Natl Compr Canc Netw (2009) 1.66
Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck (2007) 1.63
Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer (2010) 1.47
Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards. J Pain Symptom Manage (2010) 1.46
How Do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol (2000) 1.26
NIH State-of-the-Science Statement on symptom management in cancer: pain, depression, and fatigue. NIH Consens State Sci Statements (2004) 1.25
Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer (2004) 1.19
Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head Neck (2006) 1.18
Symptoms as an index of biologic behavior in head and neck cancer. Otolaryngol Head Neck Surg (1999) 0.89
Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation. Head Neck (2010) 0.89
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature (2005) 8.55
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain (2004) 4.72
Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst (2005) 4.51
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol (2012) 3.65
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys (2004) 3.21
Genome sequence of Theileria parva, a bovine pathogen that transforms lymphocytes. Science (2005) 2.71
Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol (2011) 2.70
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain (2007) 2.47
Unilateral radiotherapy for the treatment of tonsil cancer. Int J Radiat Oncol Biol Phys (2011) 2.26
Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer (2011) 2.18
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer (2002) 2.17
Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2012) 2.14
Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain (2007) 2.07
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy (2012) 2.05
Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. Ann Thorac Surg (2003) 2.05
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res (2002) 2.05
Symptoms and quality of life in diverse patients undergoing hematopoietic stem cell transplantation. J Pain Symptom Manage (2012) 1.97
Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol (2012) 1.90
A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation (2004) 1.87
Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.85
Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain (2010) 1.84
The Princeton Protein Orthology Database (P-POD): a comparative genomics analysis tool for biologists. PLoS One (2007) 1.83
Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001. Gynecol Oncol (2008) 1.78
Reinterpretation of cross-sectional images in patients with head and neck cancer in the setting of a multidisciplinary cancer center. AJNR Am J Neuroradiol (2002) 1.77
Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.75
TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res (2011) 1.71
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine (2004) 1.70
Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain (2008) 1.69
Treatment of merkel cell carcinoma. Am J Clin Oncol (2004) 1.68
Authors' reply to Tendas et al. J Pain Symptom Manage (2013) 1.66
Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol (2008) 1.66
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. J Palliat Med (2010) 1.64
Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998. Cancer (2007) 1.63
Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer (2011) 1.63
Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck (2007) 1.63
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol (2013) 1.62
Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun (2010) 1.58
MR imaging of prostate cancer in radiation oncology: what radiologists need to know. Radiographics (2013) 1.58
The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage (2002) 1.58
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs (2007) 1.53
Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys (2004) 1.53
Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol (2006) 1.52
IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys (2008) 1.51
Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PLoS One (2011) 1.51
Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys (2008) 1.51
Predicting cellular growth from gene expression signatures. PLoS Comput Biol (2009) 1.50
Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.49
Asking the community about cutpoints used to describe mild, moderate, and severe pain. J Pain (2006) 1.48
Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer (2013) 1.48
Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol (2010) 1.47
Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J (2012) 1.47
Fatigue and sleep disturbance in patients with cancer, patients with clinical depression, and community-dwelling adults. J Pain Symptom Manage (2003) 1.47
The role of statins in cancer therapy. Oncologist (2006) 1.46
Patient-reported outcomes: instrument development and selection issues. Value Health (2007) 1.46
Cancer pain management among underserved minority outpatients: perceived needs and barriers to optimal control. Cancer (2002) 1.46
LANTCET: elimination of solid tumor cells with photothermal bubbles generated around clusters of gold nanoparticles. Nanomedicine (Lond) (2008) 1.45